No products in the cart.
Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human?B-cell lymphoma for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-802
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human?B-cell lymphoma is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma.[1][2]
Detumomab is comprised of an anti-B-cell lymphomas monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.
| Products Name (INN Index) | Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human?B-cell lymphoma |
|---|---|
| INN Name | detumomab |
| Target | human?B-cell lymphoma |
| Format | Recombinant Protein |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | 0 |
| VD LC | 0 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Biogen,?Inc. (Cambridge MA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | human?B-cell lymphoma |
| Package |
Previous slide
Next slide
